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Malignant melanoma is well known for its poor re-
sponse to a variety of chemotherapeutic agents. Testing
of numerous treatment strategies has identi¢ed dacarba-
zine as the most active single drug; however, its
response rates in various clinical settings are quite
limited. Defective apoptosis in combination with
oncogenic proteins (such as activated Ras) in cell prolif-
eration pathways plays a key part in both the
development and disease progression of human mela-
noma. Farnesyl thiosalicylic acid, a novel Ras inhibitor,
dislodges Ras proteins from the cell membrane, leading
to inhibition of cell transformation and tumor growth.
In this study we evaluated the e¡ect of farnesyl thiosa-
licylic acid treatment on established human melanoma
xenografts grown in mice with severe combined im-
munode¢ciency as well as the chemosensitizing e¡ect
of farnesyl thiosalicylic acid in combination with dacar-
bazine. Daily administration of 10, 20, or 40 mg per kg
of farnesyl thiosalicylic acid resulted in a concentration-
dependent reduction in tumor growth, with growth
inhibition reaching a mean value of 4577%, at the
highest concentration. The combination of farnesyl
thiosalicylic acid (10 mg per kg per day) and dacarba-
zine (80 mg per kg per day) resulted in a signi¢cant re-
duction of 56%79%, in mean tumor growth. Analysis
of toxicologic parameters (mouse weight, blood cell
counts, and blood chemistry) showed an acceptable
and similar toxicity pro¢le for both the single-agent
farnesyl thiosalicylic acid treatment and the combina-
tion of farnesyl thiosalicylic acid plus dacarbazine treat-
ment. Given the observed preclinical treatment
responses and the low toxicity, our results support the
notion that farnesyl thiosalicylic acid in combination
with dacarbazine may qualify as a rational treatment
approach for human melanoma. Key words: dacarbazine/
farnesyl thiosalicylic acid/severe combined immunode¢ciency/
toxicity. J Invest Dermatol 120:000 ^000, 2003
M
alignant melanoma is one of the most rapidly
increasing malignancies in the white population
and has a mortality rate surpassed only by lung
cancer (Slominski et al, 2001). Age-adjusted inci-
dence rates are 12 per 100,000 in the U.S.A. and
about three times higher in some geographic areas, such as Aus-
tralia (Helmbach et al, 2001). Malignant melanoma is a tumor de-
rived from activated or genetically altered melanocytes as a result
of complex interactions between genetic, constitutional, and en-
vironmental factors (Slominski et al, 1998, 2001; Halpern and Alt-
man, 1999). Early, localized melanoma has a good prognosis after
adequate surgical therapy. The prognosis of metastatic melanoma,
however, is poor despite the availability of a growing number of
biologic, chemotherapeutic, and combined modality treatments.
Today, dacarbazine is the most widely used single-agent che-
motherapy for metastatic melanoma, but few patients obtain dur-
able responses, and the long-term survival bene¢t from this drug
is limited (Middleton et al, 2000) due to the exceptionally high
degree of drug resistance of this malignancy (Helmbach et al,
2001). Dacarbazine, a methylating agent, requires metabolic acti-
vation in the liver through an N-demethylation reaction by the
CYP450 system, and subsequently undergoes spontaneous clea-
vage to yield a stable metabolite (AIAC) and an active methylat-
ing species, diazomethane (Chabner et al, 1996; Reid et al, 1999).
Therefore, dacarbazine has no in vitro activity and is suitable only
in in vivo models. In an attempt to improve chemotherapy re-
sponse rates in malignant melanoma, numerous clinical trials
have been performed using chemotherapy (with or without in-
clusion of dacarbazine) as well as immunotherapy (with interfer-
ons7interleukin-2), gene therapy, or combinatorial strategies.
Unfortunately, it remains unclear whether any of these combina-
tion therapies is superior to single-agent dacarbazine in this dis-
ease (reviewed in Huncharek et al, 2001). Thus, new treatment
approaches are still being sought.
Although a multitude of factors have been suspected of parti-
cipating in melanoma growth, progression, and chemoresistance,
the most common speci¢c gene defects identi¢ed in melanoma
are activating mutations in Ras genes (Van’t Veer et al, 1989; Ball
et al, 1994). The incidence of Ras gene mutations in human mela-
noma is about 20% (Ball et al, 1994; van-Elsas et al, 1996), repre-
senting mainly alterations in N-Ras at codon 61, whereas
alterations in H-Ras and Ki-Ras are relatively rare (Van’t Veer
et al, 1989; Ball et al, 1994; van-Elsas et al, 1995). Because Ras proteins
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are regulators of multiple signaling pathways that control cell
growth, di¡erentiation, and apoptosis (Boguski and McCormick,
1993; Marshall, 1996; Bos, 1997), the deregulation of other cellular
factors may also mimic e¡ects of aberrant Ras function even in
the absence of a Ras mutation. Thus, the in£uence of normal
and aberrant Ras function on the biology of human melanoma
may be much greater than expected from the frequency of Ras
gene mutations in this tumor. This notion further highlights the
potential bene¢ts that Ras inhibitors may provide in attempts to
block the growth of malignant melanoma.
Improved understanding of the molecular mechanisms of Ras
processing and membrane targeting provided an important back-
ground for the development of compounds that would inhibit
the association of Ras with the inner cell membrane. Such com-
pounds include farnesyltransferase inhibitors (FTI), as well as
inhibitors of the prenyl-CAAX protease, inhibitors of
the methyltransferase, possible inhibitors of Ras tra⁄cking, and
inhibitors such as S-trans, trans farnesyl thiosalicylic acid (FTS)
that interfere with the association of mature Ras with the cell
membrane. FTI, the most widely studied group of Ras inhibi-
tors, fail to inhibit the functions of N-Ras and K-Ras proteins,
as both of these isoforms can be geranyl-geranylated under con-
ditions where the farnesyl transferase is inhibited. These alterna-
tively prenylated Ras isoforms are still targeted to the cell
membrane and remain active (Kloog et al, 1999).
The farnesyl group, which is common to all Ras proteins, may
act as part of a recognition unit for speci¢c anchorage lipids or
protein(s) that interact with Ras in the cell membrane (Cox and
Der, 1997). On the assumption that Ras functions might be in-
hibited by competitively displacing the mature protein from its
putative membrane-anchorage domains, a series of organic com-
pounds resembling the farnesylcysteine of Ras proteins was
designed (Marciano et al, 1995; Aharonson et al, 1998). One of
these compounds, FTS, was found to be a potent growth inhibi-
tor of H-Ras-transformed Rat-1 (EJ) ¢broblasts, speci¢cally
a¡ecting the membrane-bound H-Ras protein in these cells
(Marom et al, 1995; Haklai et al, 1998). Speci¢city of FTS towards
Ras was suggested by the ¢nding that FTS can inhibit the
growth of ¢broblasts transformed by ErbB2 acting upstream of
Ras, but not the growth of cells transformed by v-Raf (which,
unlike Raf-1, acts independently of Ras). FTS does not inhibit
the farnesylation of H-Ras; it a¡ects H-Ras^membrane interac-
tions both in vitro and in vivo, dislodging the protein from its
anchorage domains, thus facilitating its degradation and hence re-
ducing the total amount of cellular Ras (Marom et al, 1995;
Haklai et al, 1998).
On the basis of these proposed general mechanisms, the thera-
peutic potential of FTS was tested in vitro in several cell lines of
di¡erent origin. FTS was found to dislodge Ras proteins in all
cells investigated so far, including H-Ras-, K-Ras-, and N-Ras-
transformed rat ¢broblasts (Marom et al, 1995; Haklai et al, 1998;
Jansen et al, 1999), Rat-1 cells (Haklai et al, 1998), PC-12 cells
(Haring et al, 1998), Panc-1 cells (Weisz et al, 1999), and colon car-
cinoma cells (Halaschek-Wiener et al, 2000). Furthermore, recent
experiments showed that FTS reduces the amounts of activated
N-Ras and wild-type Ras isoforms in both human melanoma
cells and Rat-1 ¢broblasts, blocks the activity of the Ras-depen-
dent extracellular signal-regulated kinase in melanoma cells, and
inhibits the growth of N-Ras-transformed ¢broblasts and hu-
man melanoma cells in vitro and reverses their transformed phe-
notype. FTS also inhibits the growth of human melanoma cells
injected into mice with severe combined immunode¢ciency
(SCID) without evidence of drug-related toxicity (Jansen et al,
1999).
In addition to its Ras-dislodging property, FTS upregulates the
tumor suppressor protein p53 in colon cancer cells, leading to cell
cycle arrest in G0/G1 via the p53/p21
(waf1/cip1) signaling pathway
(Halaschek-Wiener et al, 2000). Taken together, these ¢ndings
support the notion that a change in the Ras-signaling cascade
leads to complex restructuring of the general survival strategies
of human cancer cells; however, H-Ras-transformed Rat-1 ¢bro-
blasts, Panc-1, and SW480 cells exposed to high concentrations of
the Ras inhibitor FTS for prolonged periods (Gana-Weisz et al,
2002) did not establish resistance against the drug. Furthermore,
it was shown that both Panc-1 and SW480 cancer cells were
highly chemosensitized to gemcitabine and doxorubicin in vitro.
Chemosensitization of Panc-1 tumors by FTS was also demon-
strated in nude mice, with a synergistic e¡ect on the survival rate
of the combined treatment of gemcitabine and FTS (Gana-Weisz
et al, 2002).
On the basis of these observations, it seemed reasonable to
speculate that FTS might chemosensitize human melanoma in
vivo. In this study we used FTS in a dacarbazine-based combina-
tion chemotherapy in a human melanoma SCID mouse xeno-
transplantation model. We evaluated the e¡ects of both single-
agent treatment with FTS or dacarbazine and combinations of
FTS and dacarbazine on established melanoma xenografts. FTS
inhibited tumor growth in a concentration-dependent manner
and chemosensitized melanomas harboring an activated N-Ras
gene. Analysis of toxicologic parameters yielded a highly favor-
able toxicity pro¢le for both single-agent FTS and combined
treatment with FTS and dacarbazine.
MATERIALS ANDMETHODS
Materials Clinical grade FTS and CRYSMEB (cyclodextrin) were
obtained fromThyreos Corporation (Newark, NJ). Dacarbazine was from
MEDAC (Hamburg, Germany). FTS was formulated in CRYSMEB,
according to the manufacturer’s instructions, to increase its solubility by
covering the hydrophobic farnesyl moiety. The stock solution of
phosphate-bu¡ered saline (PBS; Gibco, Carlsbad, CA) containing FTS in
CRYSMEB (10% wt/wt) was stable for the duration of the experiments.
CRYSMEB in PBS served as a control (‘‘carrier control’’) in all
experiments. Dacarbazine was dissolved in sterile H2O to a ¢nal
concentration of 10 mg per ml and the required amount of dacarbazine
was injected intraperitoneally.
Cell culture The human melanoma cell line 607B was obtained from
Dr Peter Schrier, Leiden, the Netherlands. These cells harbor a naturally
occurring N-Ras gene mutation (van-Elsas et al, 1995). Cells were cultured
in Dulbecco minimal Eagle’s medium (Gibco) supplemented with 10%
fetal calf serum (Gibco) in a humidi¢ed 5% CO2/95% ambient air
atmosphere at 371C. The cells needed for the experiments were grown in
culture £asks, harvested on the day of injection, counted, and diluted in
sterile PBS to a ¢nal concentration of 1107 cells per 200 ml.
Experimental animals, tumor generation, and therapy Pathogen-
free female C.B-17 scid/scid (SCID) mice, 4^6 wk old, tested for leakiness,
were obtained from Harlan-Winkelmann (Borchen, Germany). Mice were
housed in laminar £ow racks and microisolator cages under speci¢c
pathogen-free conditions and received autoclaved food and water. SCID
mice were injected subcutaneously (s.c.) into the left lower £ank with
1107 (200 ml) human melanoma cells (607B). One week after cell
inoculation, when palpable tumors were established (0.5^0.7 mm3), mice
were randomized into the respective groups (n¼ 8 in each group) and
treatment was initiated. FTS (treatment), carrier solution (CRYSMEB), or
physiologic NaCl solution (saline control) was administered daily for 4 wk
via the intraperitoneal (i.p.) route at 10, 20, or 40 mg FTS per kg. In a
combination therapy experiment FTS (10 mg per kg) was injected i.p.
daily for 2 wk, and dacarbazine (80 mg per kg) was injected i.p. on
5 consecutive days starting on day 1 of FTS treatment. This treat-
ment regimen was followed by a 2 wk observation period. Tumor size
was measured twice a week during treatment and during the observa-
tion period. Tumor volumes were calculated as follows: V
(mm3)¼ (lengthwidth2) 0.5. Four weeks after the start of treatment
the mice were killed, the tumors were isolated, and body and tumor
weights were recorded. The results (tumor weights) are presented as the
mean tumor weights (mean7SD) of eight individual mice.Whole blood
for blood cell analysis was withdrawn from mice in the combination
chemotherapy study. All animal studies were approved by the University
of Vienna AnimalWelfare Committee.
Statistical signi¢cance Statistical signi¢cance of di¡erences in mean
tumor weights (in FTS-treated or combination-treated mice compared
with controls) was determined using the Mann^Whitney U-test.
Multiple comparisons were calculated using one-way ANOVA, and
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post-tests among treatment groups were carried out using the Sche¡eŁ test
(SPSS, release 10.0.7, Chicago, IL). po0.05 was considered to be statistically
signi¢cant.
Toxicologic evaluation of FTS/dacarbazine combination
therapy Tumor-free mice of the same type as the experimental mice
were used to investigate the toxicity pro¢le of FTS (20 mg per kg) with
and without dacarbazine treatment (80 mg per kg). Mice treated with
single-agent FTS or single-agent dacarbazine (n¼ 8 per group) were
injected with the respective drugs for 3 d and were killed on day 4. Mice
receiving the drugs in combination were treated for 4 d. Mice that received
FTS plus dacarbazine combination treatment (n¼ 8 per day) were killed
on days 3, 4, and 5 after the initial drug application. Their bodies were
weighed and whole blood for blood cell analysis (n¼ 4) and serum for
enzyme activity assays (n¼ 4) was obtained.
Blood cells and serum analysis For analysis of blood cells, 0.5^0.8 ml
of whole blood was withdrawn (n¼ 4 from each group) in syringes rinsed
with heparin (Baxter, Deer¢eld, IL). Concentrations of white and red
blood cells and platelets were determined by £uorescence-activated cell
sorter analysis (FACStar, Becton-Dickinson, San Jose, CA). Serum was
isolated by centrifugation at 800 g. in an Eppendorf centrifuge at 41C
after incubation for 2 h at 41C, and analyzed for liver, pancreas, and
kidney function by standard laboratory procedures.
RESULTS
The main purpose of this study was to evaluate the therapeutic
potential and the toxicity of single-agent FTS treatment as well
as its chemosensitizing e¡ect when administered in combination
with dacarbazine. First we evaluated the therapeutic e¡ect of FTS
on established xenografts grown subcutaneously. In all the xeno-
grafted mice, xenotransplanted 607B cells grew as localized
tumors and no evidence of metastasis was observed. We
were unable to detect any metastasizing 607B melanoma cells in
the main organs removed from the mice at the end of the experi-
ments (data not shown).
Single-agent FTS treatment was initiated 1wk after cell inocu-
lation, when small tumors (0.5^0.7 mm3) were palpable. Experi-
mental animals were treated with 10, 20, or 40 mg FTS per kg or
with the carrier (CRYSMEB) or saline (physiologic NaCl) con-
trol solutions (Fig 1). After 4 wk of daily treatment, the mice
were killed and the mean tumor weights (n¼ 8 in each group)
were recorded. As shown in Fig 1(A), we observed a concentra-
tion-dependent decrease in tumor size. Carrier control treatment
had only a small e¡ect on tumor growth (the mean value was
^11%72%); the FTS-treated groups showed concentration-de-
pendent growth reduction of 31%75%, 38%78%, and
45%77% at 10, 20, and 40 mg FTS per kg, respectively, relative
to saline-treated controls. FTS treatment at 40 mg per kg resulted
in signi¢cant growth inhibition compared with both the carrier
(po0.01) and saline (po0.001) control groups, whereas mice in
the groups treated with 10 or 20 mg FTS per kg showed signi¢-
cant reductions in xenograft growth compared with the saline
control (po0.01) but not to the carrier control group. Actual
mean tumor weights (n¼ 8 mice in each group) were
1.9 g70.17 g, for the saline controls, 1.7 g70.56 g for the carrier
controls, and 1.3 g70.22 g, 1.2 g70.19 g, and 1.0 g70.16 g for the
groups treated with FTS at 10, 20, and 40 mg per kg, respectively
(Fig 1A). These results clearly demonstrate concentration-depen-
dent inhibition of mean tumor growth by FTS. Monitoring of
body weight as an indicator of toxic side-e¡ects revealed a non-
signi¢cant reduction in mean body weight at the highest dose
used (14%72% in the 40 mg FTS per kg group) (Fig 2A).
FTS reduced tumor growth in a time- and concentration-depen-
dent manner (Fig 1B): mice treated with FTS at 40 mg per kg
clearly displayed the smallest xenografts, a ¢nding that was no-
ticeable as early as day 11. Only the xenografts of mice treated
with FTS at 20 mg per kg were of similar size until day 21 (Fig
1B).
In view of these ¢ndings, we carried out follow-up experi-
ments combining dacarbazine chemotherapy with FTS to evalu-
ate the chemosensitization potential of the Ras antagonist. In the
¢rst experiment, single-agent treatment with FTS at 10 mg per
kg per day led to a small reduction in tumor growth, which was
statistically nonsigni¢cant compared with the carrier control. A
Figure1. Inhibition of human melanoma growth in SCID mice by
FTS. Mice were injected subcutaneously in the lower left £ank with
1107 607B human melanoma cells and were treated with FTS (10, 20, or
40 mg per kg, i.p., daily) for 4 wk. Treatment was initiated 1 wk after cell
inoculation, when palpable tumors were established. Control mice were si-
milarly injected with the carrier solution (carrier control) or physiologic
NaCl solution (saline control). (A) Tumor weights (mean7SD, n¼ 8)
after 4 wk of FTS administration are presented. (B) Time- and concentra-
tion-dependent growth inhibition was monitored by caliper measurements
of tumor volumes over the whole treatment period. Tumor volumes
(mean7SD, n¼ 8) are shown. An asterisk (n) indicates statistical signi¢-
cance compared with the control groups (carrier and saline), with po0.01.
Figure 2. Body weight assessment as a toxicologic indicator. Mouse
body weight (mean7SD, n¼ 8) of mice was recorded at the end of single-
agent FTS treatment (A) or combination treatment (B) experiments to
determine the toxic e¡ects of these treatment regimens. Neither the
FTS treatment shown in A nor the treatments (dacarbazine alone or in
combination with FTS) shown in B yielded a signi¢cant toxicologic e¡ect
as indicated by altered body weights.
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similar concentration (14 mg per kg per day) was previously
shown to chemosensitize e¡ectively human pancreatic carcinoma
xenotransplants (Gana-Weisz et al, 2002).
In initial toxicologic studies we determined the toxicity of
single-dose dacarbazine administration by injecting one dose of
200 mg per kg or 400 mg dacarbazine per kg (i.p.) into SCID
mice. Dacarbazine at 400 mg per kg was lethal, killing mice
within 3 d of injection. Mice injected with 200 mg dacarbazine
per kg showed clear but acceptable signs of toxicity. Combina-
tion treatment of 10 or 20 mg FTS per kg (daily for 14 d) and
200 mg dacarbazine per kg (once on day 8 of FTS treatment)
yielded high overall toxicity and resulted in only marginal reduc-
tion of tumor growth (data not shown). As a dosage of 80 mg
dacarbazine per kg administered on 5 consecutive days was pre-
viously shown by our group to be well tolerated and highly ac-
tive in a SCID mouse model (Jansen et al, 1998), we adapted this
regimen and investigated the anti-tumor e¡ect of 10 mg FTS per
kg given daily for 2 wk in combination with 80 mg dacarbazine
per kg given on days 1^5 of FTS injection. Mice treated with
carrier, carrier plus dacarbazine, single-agent dacarbazine, or sal-
ine were used as controls. The shortened FTS treatment period of
only 2 wk elicited no response in the 10 mg FTS per kg group
compared with the carrier control (Fig 3A). Tumors (n¼ 8) in
both groups showed an equal mean reduction of 20% (1.4
g70.31 g, for 10 mg FTS per kg and 1.4 g70.26 g, for the carrier)
compared with xenografts in the saline-treated group. Tumors
treated with single-agent dacarbazine (n¼ 8) were reduced by a
mean value of 32% (1.2 g70.3 g), which was exactly the same
reduction as that obtained in the tumors treated with a combina-
tion of carrier and dacarbazine (1.2 g70.3 g). Noticeably, the
combination of FTS and dacarbazine resulted in a signi¢cant re-
duction in mean tumor growth (n¼ 8) of 56% (0.7 g70.17 g;
Fig 3A; po0.008) compared with treatment with saline or
single-agent FTS or dacarbazine. These ¢ndings demonstrate that
in our human melanoma SCID xenotransplantation model the
combination of chemotherapy and FTS is clearly superior to
treatment with FTS or dacarbazine as single agents.
Di¡erences in actual tumor sizes are seen in photographs of
excised xenografts (Fig 4). These xenografts are part of the tumor
pools (n¼ 8) used for calculation of the mean tumor weights
shown in Fig 3(A). Tumors from the FTS/dacarbazine combina-
tion treatment group are much smaller than tumors from the sin-
gle-agent FTS group (10 mg per kg) or the saline control group
(Fig 4). Figure 3(B) shows the tumor development during the
treatment and observation periods. In xenografts treated with
the combination therapy growth was slowed right from the be-
ginning, and this inhibitory potential was maintained beyond
the end of treatment and until the end of the observation period.
This ¢nding clearly demonstrates the therapeutic value of the
Ras-inhibitory drug FTS in combination with the cytotoxic
agent dacarbazine over the standard chemotherapy. Mouse body
weights at the end of the observation period were similar in all
groups (Fig 2B) The saline-treated control mice were the smal-
lest, apparently because of their exceptionally large xenografts;
mean tumor weights in this group (1.7 g70.3 g) represented
about 10% of the mean whole body weight (17.5 g71.2 g). In
additional experiments, we assessed the anti-tumorigenic e¡ects
of 20 mg FTS per kg plus 80 mg dacarbazine per kg and found
that this treatment regimen, owing to higher toxicity and similar
treatment response, was not superior to the combination of 10 mg
FTS per kg and 80 mg dacarbazine per kg (data not shown).
Previous studies have shown that FTS is well tolerated (Jansen
et al, 1999;Weisz et al, 1999; Gana-Weisz et al, 2002). Dacarbazine,
however, is known for its potential toxic e¡ects, which include
hemopoietic depression causing leukopenia and thrombocytope-
nia, as well as its hepatic toxicity (Quinio et al, 1997; Loo et al,
1976; Costanzi, 1976). Analysis of blood cells to evaluate drug
toxicities at the end of the observation period revealed no di¡er-
ences between the groups. White and red blood cell counts
and platelets were not a¡ected in our model system by FTS or
dacarbazine or their combination (data not shown). These data
pointed to the low overall toxicity of the drugs 2 wk after the last
FTS injection and about 3.5 wk after the last dacarbazine
injection. To determine the immediate toxicity of these drug
Figure 3. FTS chemosensitizes human melanoma in a SCID mouse
xenotransplantation model. Mice were injected subcutaneously in the
lower left £ank with 1107 607B human melanoma cells and then treated
with FTS alone (10 mg per kg, i.p., daily for 2 wk) or dacarbazine alone (80
mg per kg, i.p., for 5 consecutive days) or a combination of FTS and da-
carbazine. Treatment was started 1wk after cell inoculation, when palpable
tumors were established. Control mice were injected with the carrier solu-
tion (carrier control), a combination of the carrier and dacarbazine, or phy-
siologic NaCl solution (saline control). (A) Tumor weights (mean7SD,
n¼ 8) 4 wk after treatment initiation (i.e., after 2 wk of drug administra-
tion and 2 wk of observation) are shown. (B) Tumor growth was moni-
tored by caliper measurement of tumor volumes during the treatment and
observation periods. Tumor volumes (mean7SD, n¼ 8) are shown. An
asterisk (n) indicates statistical signi¢cance compared with all other groups,
with po0.008.
Figure 4. Photographs of excised tumors. At the end of the combina-
tion therapy experiment the mice were killed, the tumors were removed,
and representative xenografts were photographed. Three representative tu-
mors from the saline control group, the group treated with 10 mg FTS per
kg, and the combination treatment group (10 mg FTS per kg and 80 mg
dacarbazine per kg) are shown. Scale bar¼ 2 cm.
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treatments, we treated tumor-free mice with FTS, dacarbazine, or
FTS plus dacarbazine. The mice were killed during the treatment
period (seeMaterials and Methods for details) and whole blood and
serum samples were analyzed. Erythrocyte numbers were not af-
fected by the treatment used (data not shown), whereas leukocyte
numbers decreased during the combination treatment by a mean
value of 51%712%, after 5 d. Notably, however, the same reduc-
tion was caused by dacarbazine alone (Fig 5). The combination of
FTS and dacarbazine therefore had no toxic e¡ects on bone mar-
row depression or production of white or red blood cells beyond
those elicited by dacarbazine toxicity. Similar results were
obtained for platelets, where no signi¢cant changes could be
detected in either of the treatment groups (data not shown).
Mouse body weights in all treatment groups were slightly re-
duced compared with the untreated controls. Mean body weights
recorded on the days the mice were killed showed reductions of
19%70.2%, in the group treated with FTS plus dacarbazine and
13%70.1%, in the group treated with dacarbazine alone. The
body weights of mice in all other groups were within this range
(data not shown).
Side-e¡ects in addition to hemopoietic depression (the most
common toxic side-e¡ect of dacarbazine seen in patients) include
hepatic toxicity accompanied by hepatic vein thrombosis and
hepatocellular necrosis (Loo et al, 1976; Quinio et al, 1997).
Hepatic toxicity has been observed mainly when dacarbazine has
been administered concomitantly with other anti-neoplastic
drugs, although it has also been reported in some patients treated
with dacarbazine alone. Renal dysfunction with raised retention
parameters is rather uncommon.We detected no alterations in he-
patic, renal, or pancreatic function, suggesting that our experi-
mental animals showed no immediate toxic e¡ects of FTS,
dacarbazine, or the combination of FTS and dacarbazine at the
concentrations tested (data not shown). Histologic analysis
revealed no signs of treatment-related liver pathology (data
not shown).
DISCUSSION
As oncogenic Ras is known to play a key role in chemoresistance
of human neoplasms (Jansen et al, 1997; Satyamoorthy et al, 2001),
the concept of inhibiting constitutively activated Ras in order to
chemosensitize tumors appears to be a rational one. Several ways
to inhibit Ras function have been developed. FTI were designed
to inhibit the post-translational farnesylation of Ras required for
its membrane anchorage and transforming activity (Kohl et al,
1993; Cox and Der, 1997). Anti-sense oligonucleotides that selec-
tively prevent the expression of mutated Ras proteins (Aoki et al,
1995) reduce the total cellular amount of Ras at the translational
level. Restoring catalytic activity to constitutively active Ras pro-
teins (Ahmadian et al, 1999), thereby converting them to the inac-
tive GDP-bound form (Sche¡zek et al, 1998; Ahmadian et al,
1999), as well as inhibitors of Ras e¡ector interaction (Herrmann
et al, 1998), are rather new concepts whose feasibility in Ras-direc-
ted cancer therapy has yet to be proven. FTI fail to prevent mem-
brane anchorage of the clinically important N-Ras and K-Ras
due to the alternative prenylation of these Ras isoforms via gera-
nyl-geranyl transferase under conditions where the farnesyl trans-
ferase is inhibited. Unlike FTI, FTS competes directly with all
Ras isoforms for their speci¢c membrane-binding sites, with
no obvious speci¢city for any particular isoform. So
far, FTS executed its anti-tumorigenic potential in a number of
tumor models (Haklai et al, 1998; Jansen et al, 1999; Weisz et al,
1999; Halaschek-Wiener et al, 2000). Although FTS was clearly
shown to interact with Ras proteins, we cannot rule out the pos-
sibility that inhibition of melanoma cell growth by FTS may be
associated with the inhibition not only of active Ras but also of
other prenylated proteins; however, there is no evidence to sup-
port this rather unlikely notion.
We have previously reported that FTS inhibits cell growth of
human melanoma cells, including 607B in vitro. Furthermore,
suppression of tumor growth by single-agent FTS therapy admi-
nistered immediately after tumor cell inoculation was demon-
strated in melanoma xenotransplantation models (Jansen et al,
1999). These results on single-agent FTS activity, obtained in a
more arti¢cial model system without established tumors, support
the ¢ndings reported here. In this study we evaluated the thera-
peutic potential of FTS on pre-established human melanoma
xenografts, a model that more closely mimics the clinical setting.
Treatment of subcutaneously grown tumors with 10, 20, or 40 mg
FTS per kg daily for 4 wk resulted in a concentration-dependent
reduction in mean tumor growth of 31%, 38%, and 45%, re-
spectively. These ¢ndings support our previous xenotransplanta-
tion studies demonstrating the successful activity of FTS as a
single-agent anti-neoplastic drug (Jansen et al, 1999; Weisz et al,
1999; Gana-Weisz et al, 2002).
Based on the considerations outlined above, we nevertheless
assumed that the most e¡ective application of FTS in preclinical
as well as in clinical studies was likely to be in combination with
cytotoxic drugs. Examination of this assumption was the focus
of this study. Chemotherapeutic agents are the drugs most
commonly used in clinical cancer therapy. Success rates vary
greatly, however, depending on the tumor type and the stage of
disease progression. Newer strategies of cancer treatment often
include combination chemotherapies in which speci¢c anti-tu-
mor compounds, with known mechanisms of action, are com-
bined with traditional chemotherapeutic agents (Cohen and
Falkson, 1998; Nathan and Mastrangelo, 1998; Huncharek et al,
2001). In a recent study, FTS was found to be a possible partner
in conventional chemotherapy regimens leading to chemosensiti-
zation of human colon and pancreas cancer cells in vitro and (in
the latter case) also in vivo (Gana-Weisz et al, 2002). The basic con-
cept is that oncogenic Ras leads to increased chemoresistance and
higher survival rates of cancer cells by streamlining the survival
signaling pathways and short-circuiting the natural apoptotic ma-
chinery (Serrone et al, 2000; Satyamoorthy et al, 2001). Especially
in human malignant melanoma activated N-Ras was shown to
confer chemoresistance, indicated by the ¢nding that this onco-
genic Ras isoform decreases chemotherapy-induced apoptosis in
melanoma xenotransplantation models (Jansen et al, 1997). In ad-
dition, FTS was recently shown to block human melanoma
growth through a combination of cytostatic and pro-apoptotic
e¡ects in vitro (Smalley and Eisen, 2002).We show here that com-
bination therapy of FTS and dacarbazine is signi¢cantly superior
to single-agent use of either of these drugs (see Figs 3A and 4).
Our initial experiments showed that FTS at 10 mg per kg had
only a small e¡ect on tumor growth, even when given for 4 wk
(see Fig 1A,B). In a second set of experiments we combined FTS
and dacarbazine over shorter treatment periods, and found that
Figure 5. Leukopenia induced by dacarbazine treatment.Tumor-free
mice were injected with FTS (20 mg per kg, i.p.), dacarbazine (80 mg per
kg, i.p.), a combination of FTS (20 mg per kg) and dacarbazine (80 mg per
kg), or were left untreated (naive mice). On the indicated days blood was
drawn and white blood cells were counted. Mean cell counts are presented
for control groups (naive, FTS, and dacarbazine) and for the combination
therapy group (FTS plus dacarbazine). Values are cell counts (mean7SD,
n¼ 4 per group and per time point).
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FTS at 10 mg per kg had no anti-tumor e¡ects. Dacarbazine alone
or in combination with the carrier showed a marginal response,
whereas in comparison, the combination therapy with FTS and
dacarbazine resulted in signi¢cant tumor growth reduction
(po0.008) relative to either FTS, dacarbazine or saline (see Fig
3A). Inhibition of tumor growth persisted even during the obser-
vation period after FTS treatment was stopped (see Fig 3B).
Standard treatment regimens for human melanoma include
single-agent dacarbazine as well as dacarbazine-based combina-
tion chemotherapies (Serrone et al, 2000; Huncharek et al, 2001).
Clinically, dacarbazine is administered di¡erently in European
and American treatment regimens. In the European treatment
scheme dacarbazine is administered ¢ve times at 200 mg per m2,
whereas the American regimen is 1000 mg per m2 given once.We
initially followed the American pattern and applied single doses
of 200 or 400 mg dacarbazine per kg in our experiments. The
dosage of 400 mg per kg turned out to be lethal, whereas 200
mg per kg induced toxic side-e¡ects and produced only a small
increase in the treatment response when administered in combi-
nation with FTS. Previously, however, our group reported that 80
mg dacarbazine per kg given on 5 consecutive days is well toler-
ated and highly active in SCID mice (Jansen et al, 1998). This
dacarbazine treatment scheme was also found to be suitable
in our FTS combination studies, in terms of both toxicity and
anti-tumor activity.
Based on our present results and recently described ¢ndings
(Jansen et al, 1999;Weisz et al, 1999; Halaschek-Wiener et al, 2000;
Gana-Weisz et al, 2002), we suggest that FTS has the potential
ability to interfere with mutated Ras proteins and Ras signal
transduction in a number of di¡erent cancer types, including co-
lon and pancreatic cancers and human melanoma. The Ras inhi-
bitor FTS clearly enhances the cytotoxic e¡ect of dacarbazine in
our SCID mouse model and, most notably, it does so without
contributing further to the toxicity.
Interestingly, a recent study reported a high incidence (66%) of
a somatic mis-sense mutation in the B-Raf gene of human mela-
noma, where the most frequent V599E mutation is an activating
mutation (Davies et al, 2002). As B-Raf acts downstream of Ras,
this could indicate that Ras inhibitors may not be considered as
suitable candidates for melanoma therapy. Based on current
knowledge of Ras biology and on the data presented on the acti-
vated B-Raf mutants, however, we believe that Ras inhibitors are
potentially promising therapeutic agents for human melanoma.
First, Ras is pleiotropic, activating many downstream targets
other than B-Raf, some of which (e.g., PI3-K and Ral-GEF) are
critical for maintenance of the transformed phenotype of human
tumor cells. Second, the activity of activated B-Raf mutants is
also partially Ras dependent, and is therefore enhanced by acti-
vated Ras (Davies et al, 2002). Third, although human cell lines
containing V599E B-Raf mutations do not require Ras for pro-
liferation, it is not yet clear whether or not they require Ras for
survival, invasion, and migration.
The use of speci¢c inhibitors of key cellular functions, in com-
bination with so-called ‘‘dirty’’ conventional drugs with a myriad
of mechanisms of action, might be the route to take in our quest
for improving treatment outcome. Rational combinatorial strate-
gies have led to a paradigm shift in human immunode¢ciency
virus therapy (Clumeck and De, 2000; Telenti and Paolo-Rizzar-
di, 2000), and it is reasonable to speculate that similar strategies
may prove successful in the treatment of resistant malignancies.
FTS appears well positioned to become a key tool in the ¢ght
against malignancies where mutated Ras genes and Ras signal
transduction play an important part in oncogenesis, disease pro-
gression, and treatment resistance.
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